Technical Note SBIm/SBI/SBMT: attenuated quadrivalent dengue vaccine (QDENGA®)
SBIM, in partnership with the Brazilian societies of Infectology (SBI) and Tropical Medicine (SBMT), prepared a technical note regarding the attenuated quadrivalent dengue vaccine (QDENGA®), recently approved by Anvisa for use in Brazil.
The document presents characteristics and epidemiological data of dengue and gathers information about the vaccine, such as indications, scheme and administration, contraindications, precautions, efficacy, immunogenicity and safety. Frequently asked questions are also answered.
Read: (Click here)